Seattle Genetics, Inc.

Seagen Inc.

Emergent Product Development Seattle,llc

Charles G Cerveny

Paul J Carter

Dennis R Benjamin

Charlotte McDonagh

Jeffrey A Ledbetter

Svetlana Doronina

Martha Susan Hayden-Ledbetter

William Brady

Alan F Wahl

Peter Armstrong Thompson

Philip Tan

Sandy Alexander Simon

Cecile Morales

Christy Anne Nilsson

Hans Peter Gerber

Leigh Francisco

Charlotte Mcdonagh

This invention, among other things, relates to CD19 binding agents and methods of using such CD binding agents for treating disease.

CD19 binding agents and uses thereof

This invention relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.

The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.

CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof

This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.

Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided.

Methods of treating drug-resistant cancers

This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.

Growing community of inventors

Seattle, WA, United States of America

Charles G Cerveny